Wellnex (ASX:WNX) Announces First Special Access Scheme Prescriptions for New Wellness Life Brand

2 min read | August 16, 2024 10:09 AM AEST | By Team Kalkine Media

Google News:

Image source: Shutterstock

Recent News

(ASX:VCX) Is Vicinity Centres Making Its Boldest Retail Move Yet?

Why Is Goodman Group (ASX:GMG) Powering ASX A-REITs?

Why Is Charter Hall (ASX:CHC) Defying the Property Slump?

Could MEK (ASX:MEK) Be the Small-Cap Gold Story Gathering Momentum?

Make Kalkine Media
My Trusted Source

Wellnex (ASX:WNX) has reached a significant milestone with the launch of its Wellness Life brand, now available through the Therapeutic Goods Administration's (TGA) Special Access Scheme (SAS). This marks the first set of prescriptions for Wellness Life, which officially commenced in July.

The Wellness Life brand is a product of a joint venture with OneLife Botanicals, with The Entourage Effect responsible for managing the supply to pharmacies. This collaborative effort underscores Wellnex's strategic approach to entering the medicinal cannabis market.

In addition to this milestone, Wellnex has bolstered its medical advisory team with the appointment of two esteemed professionals: Dr. Mihindu Jayasuriya and Dr. Tony Farag. Dr. Jayasuriya, previously the Chief Medical Officer at one of Australia’s leading medical cannabis franchise groups, and Dr. Farag, a seasoned holistic medical doctor and pharmacist, bring a wealth of experience to the company. Their expertise is expected to enhance the training and education of pharmacies regarding medicinal cannabis and the Wellness Life product line.

Dr. Jayasuriya and Dr. Farag are set to provide comprehensive training to selected pharmacies, furthering Wellnex's commitment to informed and effective medicinal cannabis use. This development complements the previous appointment of Dr. Sylvia Victor, adding depth to the company's advisory panel.

Wellnex's strategic advancements with Wellness Life represent a significant step forward in its mission to expand its presence in the medicinal cannabis sector, aiming to meet the growing demand for therapeutic solutions.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.